Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine and Carboplatin for Elderly Patient With Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of histologically confirmed stage IIIB or IV non-small cell lung cancer~* Good performance status (ECOG 0-1)~* No previous treatment~* Age 76 years and older~* Adequate bone marrow, liver and renal functions~* No pregnant~* Measurable disease, defined as at least one lesion whose longest diameter can be accurately measured as \>=1.0 cm by spiral CT scan~* Provided written informed consent~Exclusion Criteria:~* Severe complications or a concomitant malignancy~* Prior and other concurrent radiotherapy, chemotherapy, immunotherapy, EGFR tyrosine kinase inhibitors~* Interstitial pneumonia or lung fibrosis~* Contraindicated gemcitabine or carboplatin~* Inappropriate patients for entry to this study, judged by the physicians

- Gender: ALL
- Minimum Age: 76 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Gemcitabine 1000mg/m2 Day 1,15~Carboplatin AUC=3 Day 1, 15 every 4 weeks
- 2 (Type: ACTIVE_COMPARATOR): Gemcitabine 1000mg/m2 Day 1, 8, 15

Based on this trial design, predict the completion outcome and termination type (if applicable).